Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.
How far off is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) from its intrinsic value? Using the most recent financial...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has completed enrollment for GENERATION HD1, a global Phase 3 study evaluating the efficacy and safety of tominersen (previously IONIS-HTTRx or RG6042), an investigational antisense therapy for people living with Huntington's disease (HD).
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, today announced that it has established a $25,000 scholarship to help ALS patients in the greater San Diego area participate in a range of physical and mental wellness programs that offer an integrative approach for overcoming the challenges of disability. The Ionis Hope Scholarship will enable ALS patients to participate in group classes, massage therapy, meditation and functional movement therapy, offered by Adapt Functional Movement Center, located in Carlsbad, Calif. During the COVID-19 pandemic, Adapt is offering its full range of therapy for patients and their caregivers via live, individualized online video sessions.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement of TEGSEDI® (inotersen) in the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis.
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2020. The company reported a net loss for the first quarter ended March 31, 2020 on a GAAP basis of $43 million and on a non-GAAP basis of $36 million. Akcea had $421 million of cash, cash equivalents and short-term investments as of March 31, 2020.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human resources officer. In these roles, Ms. Poulson will be a part of the executive leadership team and provide proactive, strategic leadership and consultation across all company functions. She will also develop and drive initiatives to continue to build company culture and to support the company's business strategy.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OTTAWA , May 13, 2020 /CNW/ - Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (AKCA), today announced that it has concluded its negotiation with the pan-Canadian Pharmaceutical Alliance (pCPA) with a Letter of Intent regarding TEGSEDI™ (inoterson) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)1. Akcea Therapeutics, Inc. is a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
IONS earnings call for the period ending March 31, 2020.
Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2020 and recent business highlights.
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 6th at 11:30 a.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress.
Q1 2020 Ionis Pharmaceuticals Inc Earnings Call
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In this role, Mr. Price will oversee financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 Virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020. In consideration of the health and well-being of our stockholders, directors and employees, and in compliance with federal, state and local guidance with regards to the COVID-19 pandemic, the Annual Meeting will be held in a virtual meeting format only, via live webcast on the internet, with no physical in-person meeting this year.